"development of a small molecule drug anti-toxin therapeutic to treat anthrax in humans."
Ended Definitive Contract Awarded Last action
- Contract number
- 75N93018C00023
- Awardee
-
Hawaii Biotech, Inc. UEI ECJKEEFL4L51
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $24,623,880
Award facts
- Opportunity
-
- HHSNIHNIAIDBAA20171 Solicitation number
- Contract value 61% obligated
-
- $24,623,880.00 Current, with exercised options
- $40,358,977.00 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 24 offers Basic Research
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Honolulu, HI 96817, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$1,636 | |
| Terminate for Convenience | -$2,666,912 | |
| Supplemental Agreement for work within scope | $1,282,644 | |
| Supplemental Agreement for work within scope | -$21,379 | |
| Supplemental Agreement for work within scope | $0 | |
| Funding Only Action | -$207,821 | |
| Supplemental Agreement for work within scope | $2,139,810 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $69,252 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $4,399,101 | |
| Supplemental Agreement for work within scope | $659,542 | |
| Supplemental Agreement for work within scope | $3,958,433 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $2,888,300 | |
| Original award | $12,124,546 |
Show all 22
About this award
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a definitive contract to Hawaii Biotech, Inc. for development of a small molecule drug anti-toxin therapeutic to treat anthrax in humans on September 20, 2018, with a ceiling value of $40.358 million.
The contract carries no set-aside designation. Place of performance is Honolulu, HI. This award is structured as cost-plus-fixed-fee. The ultimate completion date is July 22, 2025, and the contract includes a de-obligation action for unexpended and expiring fiscal year 2021 funding in accordance with 31 U.S.C. Section 1552(a).
Service Contract Inventory reporting shows FY2024 labor footprint of 1.4 FTEs across 2,924 contractor hours. Government-paid blended hourly rate (including subcontractor dollars) was $556.37 per hour in FY2024. FY2021 invoiced $3.1 million across 2.3 FTEs and 4,683 hours at $667.13 per hour; FY2022 invoiced $2.4 million at $879.73 per hour; FY2023 invoiced $1.2 million at $758.81 per hour. Subcontractor teaming in FY2024 accounted for 68% of contractor hours, with one named subcontractor reported.
Quick answers
Who was awarded contract 75N93018C00023?
75N93018C00023 was awarded to Hawaii Biotech, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 20, 2018.
How much is contract 75N93018C00023 worth?
The government has obligated $24,623,880 on 75N93018C00023. Its potential value, with all options, is $40,358,977.
Was contract 75N93018C00023 competed?
The extent of competition for 75N93018C00023 was full and open competition. The government received 24 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award